Melanoma in Practice: Nurse Conference
26 July 2018
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’. Designed specifically for nurses, the presentations were designed to give nurses a better understanding of the patient experience from detection through to treatment of advanced disease and included updates in the latest areas of research that are changing the way we treat melanoma.
Presentations were given by melanoma specialists in dermatology, pathology, medical oncology, surgery, radiotherapy, physiotherapy, psychology and clinical trials, as well as melanoma survivors and CNCs who are directly involved in melanoma care
Highlights included a presentation from Associate Professor Robyn Saw who discussed the processes of surgical management of melanoma Stages 0-IV and how “understanding the anatomy is essential for diagnosing and treating melanoma”.
A key takeaway from the conference was a presentation by Associate Professor Matteo Carlino. Associate Professor Carlino delved into the system therapy for the treatment of advanced melanoma and notably pointed out how there has been a shift in nurses’ role in melanoma. “It used to be that advanced melanoma nurses worked primarily on palliative care. We're now in a time where nurses are working on survivorship care”, said Associate Professor Carlino, a statement that really resonated with the audience.
We’d like to thank those who attended and engaged with the conference. One attendee said that ‘all the sessions were so informative and the presenters had a real passion for their work’ and we hope that all attendees found it both enjoyable and beneficial.
The presentations from the Nurse Conference will be made available on our free melanoma education portal for healthcare practitioners in the next few weeks. If you’re a nurse, we encourage you to register your interest at www.melanomaeducation.org.au to be the first to know when they become available.
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
Research achievements by MIA were celebrated at the annual Sydney Medical School recently.
In this Global Research Report we showcase advances in medical oncology, reveal unexpected pathology in acral and skin melanoma, and uncover biomarkers and new gene targets for melanoma.